GPC ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Genuine Parts Company ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC)PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for ...

Core Insights - Carisma Therapeutics Inc. announced new pre-clinical data on its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna, to be presented at the SITC Annual Meeting on November 8, 2024 [1][2][3] Company Overview - Carisma Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, particularly utilizing engineered macrophages and monocytes to treat cancer and other serious diseases [5] Research and Development Highlights - The pre-clinical data indicates that the anti-GPC3 CAR-M therapy shows robust anti-tumor activity and represents a novel off-the-shelf approach for treating GPC3+ solid tumors, including HCC [2][3] - The therapy employs lipid nanoparticles to deliver mRNA encoding CARs, reprogramming endogenous myeloid cells in vivo [2] Presentation Details - The poster session at SITC will include the abstract titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma," with publication number 329, scheduled for November 8, 2024 [4]

If you have found my strategies interesting, useful, or profitable, consider supporting my continued research by joining the Cyclical Investor's Club . It's only $400/year, and it's where I share my latest research and exclusive small-and-midcap ideas. Two-week trials are free. All stock investing is about risk vs. reward over time. If an investor isn't estimating the likely reward over a given time frame, like 5 or 10 years, and then comparing that to the inflation-adjusted risk over Cory leads the investi ...

Have you evaluated the performance of Genuine Parts' (GPC) international operations for the quarter ending September 2024? Given the extensive global presence of this auto and industrial parts distributor, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth jour ...

Shares fell after the company lowered 2024 earnings expectations.Genuine Parts (GPC -2.59%) shares fell hard this week after the global automotive and industrial parts giant reported some discouraging news about its short-term operating trends. The stock fell 20% through early Thursday trading, according to S&P Global Market Intelligence, compared to a modest decline for the S&P 500 index.That performance gap was due to Genuine Parts' Q3 earnings update, which showed surprisingly weak sales and profit trend ...

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its c ...

Core Insights - The article discusses the investment position in GPC, indicating a beneficial long position through various means such as stock ownership and derivatives [1]. Group 1 - The author expresses personal opinions regarding GPC and clarifies that no compensation is received for the article, aside from Seeking Alpha [1]. - There is an emphasis on the necessity for investors to conduct their own due diligence and research before making any investment decisions [2]. - The article highlights that past performance does not guarantee future results, and no specific investment recommendations are provided [3].

For the quarter ended September 2024, Genuine Parts (GPC) reported revenue of $5.97 billion, up 2.5% over the same period last year. EPS came in at $1.88, compared to $2.49 in the year-ago quarter.The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $5.98 billion. With the consensus EPS estimate being $2.44, the EPS surprise was -22.95%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-5690 __________________________________________ GENUINE PARTS COMPANY (Exact name of registrant as specified in its charter) (State or o ...